MGMT
Methylated-DNA--protein-cysteine methyltransferase
Also known as: MGMT_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P16455
- Gene
- MGMT
- Ensembl
- ENSG00000170430
- Chromosome
- 10
- Canonical length
- 207 aa
- Protein class
- Cancer-related genes, Enzymes, Metabolic proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
Alkylating agents are potent carcinogens that can result in cell death, mutation and cancer. The protein encoded by this gene is a DNA repair protein that is involved in cellular defense against mutagenesis and toxicity from alkylating agents. The protein catalyzes transfer of methyl groups from O(6)-alkylguanine and other methylated moieties of the DNA to its own molecule, which repairs the toxic lesions. Methylation of the genes promoter has been associated with several cancer types, including colorectal cancer, lung cancer, lymphoma and glioblastoma. [provided by RefSeq, Sep 2015]
Canonical amino-acid sequenceUniProt
207 residues, UniProt reviewed canonical sequence.
>P16455|MGMT
1 MDKDCEMKRT TLDSPLGKLE LSGCEQGLHE IKLLGKGTSA ADAVEVPAPA AVLGGPEPLM
61 QCTAWLNAYF HQPEAIEEFP VPALHHPVFQ QESFTRQVLW KLLKVVKFGE VISYQQLAAL
121 AGNPKAARAV GGAMRGNPVP ILIPCHRVVC SSGAVGNYSG GLAVKEWLLA HEGHRLGKPG
181 LGGSSGLAGA WLKGAGATSG SPPAGRNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MGMT can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 126 nTPM
Expression across tissuesHPA
Tissue
- liver: 126 nTPM
- kidney: 37 nTPM
- choroid plexus: 32 nTPM
- pancreas: 30 nTPM
- adipose tissue: 30 nTPM
- breast: 28 nTPM
Single-cell type
- hepatocytes: 649 nCPM
- gastric progenitor cells: 260 nCPM
- respiratory ciliated cells: 251 nCPM
- late spermatids: 200 nCPM
- fallopian tube ciliated cells: 196 nCPM
- proximal tubule cells: 185 nCPM
Immune cell
- T-reg: 54 nTPM
- memory B-cell: 50 nTPM
- NK-cell: 50 nTPM
- naive B-cell: 48 nTPM
- gdT-cell: 44 nTPM
- plasmacytoid DC: 44 nTPM
Brain region
- choroid plexus: 19 nTPM
- medulla oblongata: 18 nTPM
- pons: 17 nTPM
- midbrain: 17 nTPM
- thalamus: 16 nTPM
- basal ganglia: 16 nTPM
ReferencesPubMed · IEDB
Publications for MGMT from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- MGMT autoantibodies as a potential prediction of recurrence and treatment response biomarker for glioma patients.
2019 · Cancer Med · RCR 0.6 · 14 citations - Experimental study of selective MGMT peptides mimicking TMZ drug resistance in glioma.
2022 · Biochem Biophys Rep · RCR 0.3 · 3 citations - A Novel IgG-IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules.
2025 · Genomics Proteomics Bioinformatics · 3 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.78
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.62
- DepMap mean gene effect
- 0.09
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- DNA alkylation repair
- DNA repair
- methylation
- negative regulation of apoptotic process
- positive regulation of double-strand break repair
Molecular functions
- DNA binding
- DNA-methyltransferase activity
- metal ion binding
- methyltransferase activity
- methylated-DNA-[protein]-cysteine S-methyltransferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Winged helix-like DNA-binding domain superfamily
- Methylated-DNA-[protein]-cysteine S-methyltransferase, active site
- Methylguanine DNA methyltransferase, ribonuclease-like domain
- Methylated-DNA-[protein]-cysteine S-methyltransferase, DNA binding
- Methylated DNA-protein cysteine methyltransferase, DNA binding domain
- Methylated DNA-protein cysteine methyltransferase domain superfamily
- 6-O-methylguanine DNA methyltransferase, DNA binding domain
- 6-O-methylguanine DNA methyltransferase, ribonuclease-like domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MGMT as an antibody target. Whether an autoantibody or antibody against MGMT could matter depends on whether native MGMT is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MGMT is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MGMT as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...